ALK and neuroblastoma: Additionally, in neuroblastoma, it has been shown that combination treatment with an ALK TKI and a p53 activator may prevent the resistance seen with ALK TKI monotherapy because the combination stimulates apoptosis rather than reversible growth arrest seen in cells treated with monotherapy [163].